Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results For Clonicel To Treat ADHD
A drug that diminishes the body’s hyper-reactivity to stress has been shown to significantly reduce symptoms of attention-deficit hyperactivity disorder (ADHD) in children, according to a phase 3 clinical trial conducted by Addrenex Pharmaceuticals.
More: continued here
Filed under: ADHD on September 22nd, 2008